Brigette Ma

Summary

Affiliation: The Chinese University of Hong Kong
Country: China

Publications

  1. ncbi request reprint The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute, Chinese University of Hong Kong, Shatin, Hong Kong
    Invest New Drugs 28:413-20. 2010
  2. ncbi request reprint Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type
    Sing Fai Leung
    Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Cancer 98:288-91. 2003
  3. pmc Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
    Brigette B Y Ma
    Department of Clinical Oncology, Cancer Drug Testing Unit, State Key Laboratory in Oncology in South China, Hong Kong Cancer Institute, Sir YK Pao Centre for Cancer, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
    Invest New Drugs 28:326-33. 2010
  4. pmc Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer
    Herbert H Loong
    Department of Clinical Oncology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    J Oncol 2009:967920. 2009
  5. ncbi request reprint Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region Electronic address
    Cancer Lett 343:24-32. 2014
  6. doi request reprint Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute, Chinese University of Hong Kong, Shatin, Hong Kong, China
    Invest New Drugs 31:567-75. 2013
  7. doi request reprint Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China
    Invest New Drugs 31:30-8. 2013
  8. doi request reprint A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma
    B B Y Ma
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China
    Ann Oncol 23:1287-92. 2012
  9. doi request reprint Novel systemic therapeutic for nasopharyngeal carcinoma
    Stephen L Chan
    The Chinese University of Hong Kong, Hong Kong Cancer Institute and Prince of Wales Hospital, Sir YK Pao Center for Cancer, Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Shatin, Hong Kong
    Expert Opin Ther Targets 16:S63-8. 2012
  10. pmc Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma
    Stephen L Chan
    Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, 30 32 Ngan Shing Street, Shatin, Hong Kong SAR, China
    BMC Cancer 6:259. 2006

Detail Information

Publications21

  1. ncbi request reprint The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute, Chinese University of Hong Kong, Shatin, Hong Kong
    Invest New Drugs 28:413-20. 2010
    ..AKT upregulation following RAD001 treatment suggests the presence of a feedback loop on AKT signaling in NPC which warrants further investigation...
  2. ncbi request reprint Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type
    Sing Fai Leung
    Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong
    Cancer 98:288-91. 2003
    ..This issue has management implications because different therapeutic strategies currently are employed for patients with good-risk and those with poor-risk NPC...
  3. pmc Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response
    Brigette B Y Ma
    Department of Clinical Oncology, Cancer Drug Testing Unit, State Key Laboratory in Oncology in South China, Hong Kong Cancer Institute, Sir YK Pao Centre for Cancer, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
    Invest New Drugs 28:326-33. 2010
    ....
  4. pmc Update in antiepidermal growth factor receptor therapy in the management of metastatic colorectal cancer
    Herbert H Loong
    Department of Clinical Oncology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong
    J Oncol 2009:967920. 2009
    ..Novel strategies of targeting the EGFR pathway to improve efficacy as well as ongoing research in identifying specific molecular predictors of response will be discussed...
  5. ncbi request reprint Preclinical evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal cancer models
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong Special Administrative Region Electronic address
    Cancer Lett 343:24-32. 2014
    ..A daily schedule was more effective than a weekly schedule on tumor growth and inhibition of downstream mTOR signaling in vivo. The activity of BEZ235 maybe independent of the PIK3CA amplification and mutation status...
  6. doi request reprint Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute, Chinese University of Hong Kong, Shatin, Hong Kong, China
    Invest New Drugs 31:567-75. 2013
    ..In summary, MK-2206 can inhibit growth and abrogate AKT and mTOR signaling in NPC cell lines. This agent is currently being evaluated in a phase II study in metastatic NPC...
  7. doi request reprint Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Cancer Drug Testing Unit, Hong Kong Cancer Institute and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, Hong Kong, China
    Invest New Drugs 31:30-8. 2013
    ..This result suggests that selumetinib alone or in combination with gefitinib or cisplatin maybe a promising strategy against NPC. Further studies are warranted...
  8. doi request reprint A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma
    B B Y Ma
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China
    Ann Oncol 23:1287-92. 2012
    ....
  9. doi request reprint Novel systemic therapeutic for nasopharyngeal carcinoma
    Stephen L Chan
    The Chinese University of Hong Kong, Hong Kong Cancer Institute and Prince of Wales Hospital, Sir YK Pao Center for Cancer, Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Shatin, Hong Kong
    Expert Opin Ther Targets 16:S63-8. 2012
    ..Therefore, novel therapies based on molecular targets of NPC have become the focus of development...
  10. pmc Radiological, pathological and DNA remission in recurrent metastatic nasopharyngeal carcinoma
    Stephen L Chan
    Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, 30 32 Ngan Shing Street, Shatin, Hong Kong SAR, China
    BMC Cancer 6:259. 2006
    ..The mainstay of treatment of metastatic NPC is systemic chemotherapy and resection for solitary metastasis. Despite high response rate to chemotherapy, complete remission is uncommonly seen...
  11. doi request reprint The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
    Brigette B Y Ma
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, China
    Invest New Drugs 28:107-14. 2010
    ..This study provided the basis for a phase II clinical trial of PXD101 in inoperable hepatitis-B associated HCC...
  12. ncbi request reprint A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells
    Brigette Ma
    Department of Clinical Oncology, Sir Y K Pao Center for Cancer, Hong Kong Cancer Institute, State Key Laboratory in Oncology in South China, Chinese University of Hong Kong, Ngan Shing Street, Shatin, New Territories, Hong Kong
    Invest New Drugs 26:169-73. 2008
    ..We tested the hypothesis that 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) may enhance response to re-treatment with gemcitabine by enhancing intracellular uptake of gemcitabine in a phase II study...
  13. ncbi request reprint A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy
    Brigette Ma
    Department of Clinical Oncology and Sir Y K Pao Cancer Center, Prince of Wales Hospital, Shatin, Hong Kong
    Cancer Chemother Pharmacol 62:59-64. 2008
    ..The epidermal growth factor receptor (EGFR) is commonly overexpressed in nasopharyngeal carcinoma (NPC) and gefitinib inhibits NPC growth in vitro...
  14. ncbi request reprint Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma
    Brigette B Y Ma
    Department of Clinical Oncology, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR, China
    Expert Rev Anticancer Ther 6:383-94. 2006
    ....
  15. ncbi request reprint Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma
    Brigette B Y Ma
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China
    Cancer 103:22-31. 2005
    ....
  16. ncbi request reprint Prospective validation of serum CYFRA 21-1, beta-2-microglobulin, and ferritin levels as prognostic markers in patients with nonmetastatic nasopharyngeal carcinoma undergoing radiotherapy
    Brigette B Y Ma
    Department of Clinical Oncology, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China
    Cancer 101:776-81. 2004
    ..The prognostic value of these markers has never been validated prospectively...
  17. ncbi request reprint The prognostic significance of tumor vascular invasion and its association with plasma Epstein-Barr virus DNA, tumor volume and metabolic activity in locoregionally advanced nasopharyngeal carcinoma
    Brigette B Y Ma
    Department of Clinical Oncology, Sir Y K Pao Centre for Cancer, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, China
    Oral Oncol 44:1067-72. 2008
    ..Parapharyngeal and cavernous sinus invasion were not significant predictors of distant recurrence following chemoradiotherapy in our cohort with locoregionally advanced NPC...
  18. ncbi request reprint A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma
    Winnie Yeo
    Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China
    J Natl Cancer Inst 97:1532-8. 2005
    ..Cisplatin, interferon, doxorubicin, and fluorouracil (PIAF) used in combination, by contrast, has shown promise in a phase II study. We compared doxorubicin to PIAF in patients with unresectable HCC in a phase III trial...
  19. doi request reprint Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization
    Simon Chun Ho Yu
    From the Department of Imaging and Interventional Radiology S C H Y, J W Y H, Vascular and Interventional Radiology Foundation Clinical Science Center S C H Y, J W Y H, Department of Clinical Oncology S L C, F M, B M, T M, W Y, and Department of Surgery P L, The Chinese University of Hong Kong, Room 2A061, 2 F, New Extension Block, Prince of Wales Hospital, 30 32 Ngan Shing St, Shatin, New Territories, Hong Kong SAR and Departments of Clinical Oncology E P H and Surgery K F L, J W, Prince of Wales Hospital, Shatin, Hong Kong SAR
    Radiology 270:607-20. 2014
    ....
  20. ncbi request reprint Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer -- a retrospective review of Chinese patients and comparison with an historic Western series
    Brigette Ma
    Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Shatin, NT, Hong Kong
    Radiother Oncol 62:185-9. 2002
    ..The higher incidence of hepatoxicity was possibly associated with endemic chronic hepatitis B infection in this geographical area...
  21. ncbi request reprint [EGF receptor blockade with monoclonal antibodis and so-called "small molecules"]
    Fortunato Ciardiello
    Division of Medical Oncology, Department of Clinical and Experimental Medicine, Seconda Universita di Napoli, Naples, Italy
    Onkologie 28:18-24. 2005